Investor Presentaiton

Balancing rapid Shield growth with measured spend over next 5 years Annual cash burn ~$200M over 5 years INVESTOR 20 DAY 23 • • $ ASP > $500 Medicare ADLT rate Incremental private payer coverage based on ACS recommendations Full private payer coverage following USPSTF guidelines GUARDANT™ R&D Lung and MCED • % Gross Margins Positive 1 year post launch . ~60% at 1M annual volume CapEx Low cost, high volume, automated lab operations Phased CapEx investments Leverage Smart Liquid Biopsy platform SG&A • Efficient sales & marketing model / milestone gated investments Leverage Guardant back-office infrastructure 151

View entire presentation